Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BPTSY OTCMKTS:OMGAQ NASDAQ:PRFX NASDAQ:VRAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPTSYBiophytis$0.25$0.37$0.00▼$2.08$587K2.461,154 shsN/AOMGAQOmega Therapeutics$0.00$0.00$0.00▼$1.69$166K0.57215,590 shsN/APRFXPainReform$1.58$2.29$1.50▼$17.95$640K0.7777,571 shs25,616 shsVRAXVirax Biolabs Group$0.15+9.6%$0.16$0.10▼$1.19$670K1.064.51 million shs1.69 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPTSYBiophytis0.00%0.00%0.00%-50.00%-87.98%OMGAQOmega Therapeutics0.00%0.00%0.00%0.00%-97.60%PRFXPainReform0.00%-18.56%-41.04%-46.62%-83.88%VRAXVirax Biolabs Group0.00%-10.23%+1.32%-25.70%-85.85%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPTSYBiophytis$0.25$0.37$0.00▼$2.08$587K2.461,154 shsN/AOMGAQOmega Therapeutics$0.00$0.00$0.00▼$1.69$166K0.57215,590 shsN/APRFXPainReform$1.58$2.29$1.50▼$17.95$640K0.7777,571 shs25,616 shsVRAXVirax Biolabs Group$0.15+9.6%$0.16$0.10▼$1.19$670K1.064.51 million shs1.69 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPTSYBiophytis0.00%0.00%0.00%-50.00%-87.98%OMGAQOmega Therapeutics0.00%0.00%0.00%0.00%-97.60%PRFXPainReform0.00%-18.56%-41.04%-46.62%-83.88%VRAXVirax Biolabs Group0.00%-10.23%+1.32%-25.70%-85.85%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPTSYBiophytis 0.00N/AN/AN/AOMGAQOmega Therapeutics 0.00N/AN/AN/APRFXPainReform 1.00SellN/AN/AVRAXVirax Biolabs Group 2.00Hold$1.00551.47% UpsideCurrent Analyst Ratings BreakdownLatest OMGAQ, PRFX, VRAX, and BPTSY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026PRFXPainReform Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/8/2026VRAXVirax Biolabs Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPTSYBiophytisN/AN/AN/AN/A($16.18) per shareN/AOMGAQOmega Therapeutics$3.09M0.05N/AN/A$1.05 per share0.00PRFXPainReform$20K31.60N/AN/A$23.07 per share0.07VRAXVirax Biolabs Group$10K66.62N/AN/A$1.26 per share0.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPTSYBiophytis-$18.43MN/AN/AN/AN/AN/AN/AN/AN/AOMGAQOmega Therapeutics-$97.43M-$1.33N/AN/AN/AN/AN/AN/AN/APRFXPainReform-$5.02M-$736.66N/AN/AN/AN/AN/AN/AN/AVRAXVirax Biolabs Group-$6.06MN/AN/AN/AN/AN/AN/AN/A6/3/2026 (Estimated)Latest OMGAQ, PRFX, VRAX, and BPTSY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/3/2026N/AVRAXVirax Biolabs Group-$0.07N/AN/AN/A$0.00 millionN/A4/6/2026Q4 2025PRFXPainReform-$612.00-$0.9850+$611.0150-$0.9850N/AN/A3/26/2026Q4 2025PRFXPainReformN/A-$1.01N/A-$1.01N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBPTSYBiophytisN/AN/AN/AN/AN/AOMGAQOmega TherapeuticsN/AN/AN/AN/AN/APRFXPainReformN/AN/AN/AN/AN/AVRAXVirax Biolabs GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPTSYBiophytisN/A0.41N/AOMGAQOmega TherapeuticsN/AN/AN/APRFXPainReformN/A1.781.78VRAXVirax Biolabs GroupN/A11.3711.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPTSYBiophytis0.05%OMGAQOmega Therapeutics97.47%PRFXPainReform37.28%VRAXVirax Biolabs Group8.61%Insider OwnershipCompanyInsider OwnershipBPTSYBiophytis3.70%OMGAQOmega Therapeutics8.50%PRFXPainReform34.40%VRAXVirax Biolabs Group45.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBPTSYBiophytis302.35 million338,000N/AOMGAQOmega Therapeutics12055.37 million50.66 millionOptionablePRFXPainReform4400,000264,000Not OptionableVRAXVirax Biolabs Group54.34 million2.38 millionNot OptionableOMGAQ, PRFX, VRAX, and BPTSY HeadlinesRecent News About These CompaniesAvalon Advanced Materials and Virax Biolabs Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVMay 15 at 10:01 AM | corsicanadailysun.comCVirax Biolabs Group Ltd - Ordinary Shares - Class AMay 13, 2026 | money.usnews.comVirax Biolabs Group Limited Or Stock Short Interest Rises to 71.68%April 25, 2026 | quiverquant.comQVirax Biolabs Group Ltd. Class AApril 24, 2026 | edition.cnn.comVirax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to ShareholdersApril 14, 2026 | prnewswire.comVirax Biolabs Announces Full Exercise of Pre-Funded Warrants From $5 Million Private PlacementApril 10, 2026 | tipranks.comWhat's Behind The Jump In Virax Biolabs Stock?March 31, 2026 | benzinga.comVirax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical ValidationMarch 31, 2026 | prnewswire.comVirax Biolabs Group (VRAX) price target decreased by 95.00% to 1.02February 5, 2026 | msn.comVirax Biolabs Sets March 11, 2026 AGM to Vote on Reverse Share Split and New Equity PlanJanuary 30, 2026 | tipranks.comVirax Biolabs Group Limited (VRAX) Upgraded to Buy: Here's WhyJanuary 15, 2026 | zacks.comVirax Biolabs secures $5 million in private placement to advance immunology researchDecember 4, 2025 | msn.comVirax Biolabs Group Limited Announces Closing of $5 Million Private PlacementDecember 4, 2025 | prnewswire.comVirax Biolabs Group Limited Announces $5 Million Private PlacementDecember 3, 2025 | prnewswire.comVirax Biolabs stock rockets after clinical progress in post-infection diagnosticsDecember 3, 2025 | investing.comVirax Biolabs soars as company advances diagnostics for post-infection syndromesDecember 3, 2025 | msn.comVirax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to ShareholdersDecember 3, 2025 | prnewswire.comVirax BioLabs Group Limited: Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune Study Evaluating T Cell Dysfunction in Post ...November 3, 2025 | finanznachrichten.deVirax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection SyndromesNovember 3, 2025 | prnewswire.comVirax Biolabs (VRAX) Falls 18% on Lack of LeadsAugust 27, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOMGAQ, PRFX, VRAX, and BPTSY Company DescriptionsBiophytis NASDAQ:BPTSY$0.25 0.00 (0.00%) As of 05/15/2026Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.Omega Therapeutics OTCMKTS:OMGAQ$0.0030 0.00 (0.00%) As of 05/15/2026Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.PainReform NASDAQ:PRFX$1.58 0.00 (0.00%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$1.56 -0.02 (-1.14%) As of 05/15/2026 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.Virax Biolabs Group NASDAQ:VRAX$0.15 +0.01 (+9.64%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$0.15 -0.01 (-4.89%) As of 05/15/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Peloton Stock Gives Back Gains After Upbeat Earnings Report MarketBeat Week in Review – 05/11 - 05/15 Datavalut Gains Traction: 5 Reasons to Sell Now TMC Stock: Why This Pre-Revenue Miner Is Worth Watching Alphabet's Googlebook Brings Gemini AI to PC Hardware As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In Robinhood, SoFi, and Webull Are Telling Very Different Stories Viking Sails to All-Time Highs—Fundamentals Signal More to Come Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
